- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01161498
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEX^GM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE1 7EH
- The Royal Marsden Hospital
-
-
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Investigative Clinical Research of Indiana
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- James Graham Brown Cancer Center, University of Louisville
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical Univesity of South Carolina
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- VCU Massey Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥ 18 years
- Eastern Co-Operative Oncology Group (ECOG) Performance Status ≤ 1
- Histological evidence (from the primary lesion and/or lymph nodes) of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx
- Stage III or IV disease (T2N2-3M0, T3-4N1-3M0)
- No evidence of distant metastases by computed tomography (CT) or positron emission tomography (PET)/CT scan
- Life expectancy > 4 months
- Neutrophil count ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 10 g/dL
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Creatinine clearance ≥ 60 mL/min
- Female patients of child-bearing potential (i.e. not surgically sterile, or not having spontaneous amenorrhea for at least 12 months) must agree to use an effective form of contraception during the treatment phase of the study.
- Male patients must agree to use a condom with spermicide or their female partner must use an effective method of birth control.
- Provide written informed consent in accordance with all applicable regulations and follow the study procedures. Patients must be capable of understanding the investigational nature, potential risks and benefits of the study.
Exclusion Criteria:
- Prior treatment for locally advanced SCCHN (No prior surgery for SCCHN except nodal sampling or biopsy for study disease).
- Patients with T1-2N1 or T1N2-3.
- Pre-existing peripheral neuropathy ≥ Grade 2 (motor or sensory).
- Weight loss > 20% of body weight within 3 months of screening (unless purposeful).
- Surgery ≤ 28 days before randomization with the exception of feeding tube placement, dental extractions, central venous catheter placement, biopsies and nodal sampling.
- Cancer of the nasopharynx, sinus, salivary gland or skin.
- Previous radical radiation therapy (RT) to the head and neck region, excluding superficial RT for a non-melanomatous skin cancer.
- Prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.
- Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as human immunodeficiency (HIV) infection, cardiac failure, pulmonary compromise (chronic obstructive pulmonary disease, pneumonia or respiratory decompensation) resulting in hospitalization within 12 months of screening, or active infection.
- Any significant cardiac disease (e.g., New York Heart Association (NYHA) Class 3 or 4; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty or coronary artery bypass graft (CABG) within the past 6 months; or uncontrolled atrial or ventricular cardiac arrhythmias..
- High risk for poor compliance with therapy or follow up as assessed by the investigator.
- Active herpes labialis, other lesions due to herpes simplex virus type I (HSV1) or dermatoses involving or within 50 cm of the lesions to be injected; active HSV1 lesions must have resolved before talimogene laherparepvec is injected.
- Prior systemic chemotherapy for any type of cancer.
- Patients for whom radiation therapy is contraindicated.
- Pregnant or breast-feeding female. Confirmation that women of child-bearing potential are not pregnant. A negative serum β- human chorionic gonadotropin (β-hCG) pregnancy test result must be obtained during the screening period.
- Currently enrolled and receiving an investigational agent in a clinical research study or received an investigational agent for any reason within 4 weeks prior to screening.
- Require intermittent or chronic treatment with an anti-herpetic drug (e.g., acyclovir), other than intermittent topical use.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Radiation/Cisplatin
Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42.
Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
|
70 grays of radiation administered in 35 fractions over 7 weeks
Administered by intravenous infusion
|
EXPERIMENTAL: Talimogene Laherparepvec + Radiation/Cisplatin
The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63.
Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
|
70 grays of radiation administered in 35 fractions over 7 weeks
Administered by intravenous infusion
Administered by intratumoral injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year Event-free Survival
Time Frame: 2 years
|
Event-free survival is defined as the time from randomization until the first evidence of relapse, disease progression (local, regional, metastatic, or second primary), or death from any cause.
Because this study was terminated with only 5 participants enrolled, and the study was terminated in the first year, this endpoint was not analyzed.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Objective Response (cOR)
Time Frame: End of trial; the maximum time on study was 20 weeks.
|
Tumor response was assessed by computed tomography (CT) scan according to a modified version of the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1). Objective response is defined as achieving a clinical partial response (cPR) or complete response (cCR). cCR is defined as disappearance of all baseline lesions. Any pathological lymph nodes must have a reduction in short axis to < 10 mm. cPR is defined as at least a 30% decrease in the sum of diameters of baseline lesions. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of baseline lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or the appearance of any new lesions. Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the cOR rate was not calculated. Therefore a summary of response at the end of study is reported. |
End of trial; the maximum time on study was 20 weeks.
|
Metabolic Complete Response (mCR)
Time Frame: End of study; the maximum time on study was 20 weeks.
|
Response to therapy was assessed using [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) imaging to detect metabolically active tumors. Metabolic complete response (mCR) is defined as complete disappearance of FDG uptake attributable to tumor compared to baseline scan. Partial metabolic response (mPR) is defined as a > 40% decrease in specific uptake compared to the initial value in over half of the lesions. Disease progression (mPD) is defined as a specific uptake increase in any lesion, appearance of new lesions, or presence of extended areas of disease activity. Stable metabolic response (mSD) is defined as a decrease in uptake < 40% of the initial value of over half the lesions. Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the metabolic complete response rate was not calculated. Therefore a summary of metabolic response at end of study is reported. |
End of study; the maximum time on study was 20 weeks.
|
Pathologic Complete Response (mCR)
Time Frame: Up to Week 20
|
Response to therapy was assessed histopathologically from biopsies taken at surgery for those participants who had surgery prior to Week 22. If no viable tumor cells were identified in surgical specimens (where the patient had surgery) the patient was classified as having a pathological complete response (pCR), and if viable tumor cells were identified, the patient was classified as having an incomplete pathologic response. Because this study was terminated with 5 patients enrolled, data for this endpoint were summarized in by-patient listings only and the pathologic complete response rate was not calculated. Therefore a summary of participants with a pathologic complete response before the end of study is reported. |
Up to Week 20
|
Time to Locoregional Failure
Time Frame: Up to 27 months
|
Locoregional failure is defined as disease progression in the head and neck area at any time following completion of chemoradiotherapy. Because this study was terminated with 5 subjects enrolled, time to locoregional failure was not analyzed. |
Up to 27 months
|
Time to Distant Failure
Time Frame: Up to 27 months
|
Distant failure is defined as disease progression at any site other than the head and neck area at any time following completion of chemoradiotherapy. Because this study was terminated with 5 participants enrolled, time to distant failure was not analyzed. |
Up to 27 months
|
Time to Any Failure
Time Frame: Up to 27 months
|
Any failure is defined as disease progression at any site at any time following completion of chemoradiotherapy. Because this study was terminated with 5 participants enrolled, time to any failure was not analyzed. |
Up to 27 months
|
Overall Survival
Time Frame: Up to 5 years after chemoradiotherapy
|
Overall survival is defined as the time from randomization to death from any cause. Because this study was terminated with 5 participants enrolled, overall survival was not analyzed. |
Up to 5 years after chemoradiotherapy
|
Disease-specific Survival
Time Frame: Up to 5 years after chemoradiotherapy
|
Disease-specific survival is defined as the time from randomization to death of the patient due to the cancer under study. Because this study was terminated with 5 participants enrolled, disease-specific survival was not analyzed. |
Up to 5 years after chemoradiotherapy
|
Participants With N1-2 Disease at Baseline Requiring Neck Dissection
Time Frame: Weeks 19 - 21
|
Participants with Baseline Nl or N2 disease (lymph node metastasis not more than 6 cm in greatest dimension) with persistent disease as determined at the post chemoradiotherapy assessment of response were to proceed to neck dissection as permitted by the institution no later than Week 22. Since this study terminated prematurely neck dissection data were not collected or analyzed.
|
Weeks 19 - 21
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kevin Harrington, MD, Royal Marsden, UK
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 006/09
- 20110130 (OTHER: Amgen Inc.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Radiation
-
Cancer Institute and Hospital, Chinese Academy...Terminated
-
Massachusetts General HospitalCompletedMesenchymal TumorUnited States
-
Canadian Cancer Trials GroupAlliance for Clinical Trials in Oncology; NRG Oncology; Eastern Cooperative Oncology... and other collaboratorsRecruitingBreast CancerUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
University of Texas Southwestern Medical CenterCompletedNon-small Cell Lung CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
Maastricht Radiation OncologyThe Netherlands Cancer Institute; Diakonessenhuis, UtrechtCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States